icad inc. Debt/Equity
Debt/Equity of ICAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.
Debt/Equity for the quarter ending September 29, 2020 was 0.27 (a 1.37% increase compared to previous quarter)
Year-over-year quarterly Debt/Equity decreased by -91.39%
Annual Debt/Equity for 2019 was 3.09 (a 89.56% increase from previous year)
Annual Debt/Equity for 2018 was 1.63 (a 351.48% increase from previous year)
Annual Debt/Equity for 2017 was 0.36 (a Infinity% increase from previous year)
Visit stockrow.com/ICAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Debt/Equity of icad inc.
Most recent Debt/Equityof ICAD including historical data for past 10 years.
Interactive Chart of Debt/Equity of icad inc.
icad inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)
2020 – 0.27 0.26 0.46 –
2018 1.9 0.49 0.5 0.53 1.63
2017 0.36 0.31 0.0 0.0 0.36
2016 0.0 0.0 0.0 0.02 0.0
2015 0.0 0.01 0.01 0.01 0.0
2011 0.0 0.0 0.0 0.0 0.0
Business Profile of icad inc.
Industry: Health Information Services
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which offers automated, consistent, and standardized reporting tool used for mammogram. It also provides ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound Panorama, a prototype software product for determining risk factors in interval cancers; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.